Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eduardo Sabate

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The American Journal of Nursing|May 29, 2004
Therapy adherenceMeg Smirnoff, Nancy R Reynolds, Eduardo Sabate
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 20, 2021
Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic ModelingFelicitas Kuehne, Ursula Rochau, Noman Paracha, et al.
The Lancet. Oncology|January 22, 2013
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trialDan Stark, Matthew Nankivell, Eric Pujade-Lauraine, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The American Journal of Nursing|May 29, 2004
Therapy adherenceMeg Smirnoff, Nancy R Reynolds, Eduardo Sabate
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 20, 2021
Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic ModelingFelicitas Kuehne, Ursula Rochau, Noman Paracha, et al.
The Lancet. Oncology|January 22, 2013
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trialDan Stark, Matthew Nankivell, Eric Pujade-Lauraine, et al.
Pageof 1